ライフサイエンスコーパス: direct oral anticoagulant

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 These findings support the continued use of direct oral anticoagulants.

2 The role of treatment with direct oral anticoagulant agents is unclear.

3 Sex-specific comparative effectiveness of direct oral anticoagulants among patients with nonvalvul

4 clopidogrel, a vitamin K antagonist (VKA), a direct oral anticoagulant, and combined antithrombotic d

5 Direct oral anticoagulants are increasingly used for a w

6 Direct oral anticoagulants are non-inferior to conventio

7 %; adjusted OR, 1.87 [95% CI, 1.57-2.24]), a direct oral anticoagulant (cases: 1.0%, controls: 0.6%;

8 k of gastrointestinal bleeding with use of a direct oral anticoagulant compared with warfarin or low-

9 risk of major gastrointestinal bleeding with direct oral anticoagulants compared with warfarin or low

10 risk of major gastrointestinal bleeding with direct oral anticoagulants compared with warfarin or low

11 With the introduction of direct oral anticoagulants (dabigatran, rivaroxaban, api

12 risk of major gastrointestinal bleeding with direct oral anticoagulants did not differ from that with

13 Although direct oral anticoagulants do not need laboratory testin

14 BACKGROUND & AIMS: Direct oral anticoagulant (DOAC) agents increase the ris

15 Direct oral anticoagulant (DOAC) agents increase the ris

16 with venous thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K antagoni

17 ompare causes of death in patients receiving direct oral anticoagulants (DOAC) or warfarin for preven

18 , provided validation for the development of direct oral anticoagulants (DOAC), and currently such in

19 Direct oral anticoagulants (DOACs) are attractive option

20 Evidence regarding the use of direct oral anticoagulants (DOACs) in the elderly, parti

21 The availability of direct oral anticoagulants (DOACs) may improve overall O

22 The direct oral anticoagulants (DOACs) represent a major adv

23 The recently FDA-approved direct oral anticoagulants (DOACs), such as dabigatran,

24 Despite the introduction of direct oral anticoagulants (DOACs), the search for more

25 The rapid global adoption of direct oral anticoagulants for management of VTE in pati

26 The availability of direct oral anticoagulants further complicates decision

27 e improvements linked to the introduction of direct oral anticoagulants, more than one third of atria

28 would derive a greater safety benefit with a direct oral anticoagulant rather than warfarin.

29 e sex-specific, comparative effectiveness of direct oral anticoagulants (rivaroxaban and dabigatran),

30 data on the relative efficacy and safety of direct oral anticoagulants, such as edoxaban, compared w

31 d the risk of gastrointestinal bleeding with direct oral anticoagulants, warfarin, and low-molecular-

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。